GE HealthCare announces updates to its Intelligent Radiation Therapy (iRT) platform, designed to optimize workflows in radiation oncology. The AI-based tool, which is interoperable with third-party systems, aims to drastically reduce the time between diagnosis and treatment through the automation of manual tasks, analytics, and intelligent resource planning. NB: cp -5.5%.
According to Ben Newton, general manager of Oncology Solutions, iRT makes it possible to move "from diagnosis to treatment in minutes, not days." Early users have reduced planning time from 7 days to 7 minutes with RayStation integration.
GE HealthCare is also unveiling an extension of iRT dedicated to theranostics, an approach that combines precision imaging (diagnosis) and targeted treatments (therapy). The goal is to manage the complex steps of these treatments in an integrated manner, from clinical evaluation to drug dosing.
The group will also present the latest developments in its MIM Maestro and iRT MR Direct solutions at the ASTRO 2025 conference in San Francisco, confirming its ambition to improve the precision and effectiveness of cancer care.
GE HealthCare Technologies Inc. is a medical technology, pharmaceutical diagnostics, and digital solutions company. The Company provides integrated solutions, services, and data analytics. Its segments include Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its Ultrasound segment includes ultrasound medical devices and solutions with a portfolio of continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. The segment also includes the clinical artificial intelligence (AI) software business. Its PCS segment portfolio consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment consists of two business lines: contrast media and molecular imaging.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
